Sağlıkta büyük verinin önemi

Year 2018, Volume: 10 Issue: 2, 216 - 219, 01.06.2018

Akif Altınbaş

https://doi.org/10.21601/ortadogutipdergisi.412200

Abstract

Bilgi toplumunda beklendiği üzere veri
depolanması hızlı bir şekilde artmakta ve bu devasa veri birikimini en etkin
bir şekilde kullanarak eldeki mevcut sınırlı finansal ve insan gücü
kaynaklarını verimli değerlendirmenin yolları aranmaktadır. Bunu yaparken bize
lazım olan, analiz için etkinliği ispatlanmış bilimsel metotların varlığı ve
tabii ki değerlendirmeye tabii tutulacak büyük veri depolarının varlığıdır.
Ülkemiz veri depolanması konusunda son yıllarda çok önemli mesafe almıştır.
Sağlık Bakanlığı ve Sosyal Güvenlik Kurumu bünyesinde kurulan sağlık verileri,
hem sağlık politikalarına yön verme konusunda hem de ülkemizin bilimsel
gelişimine katkı sunacak şekilde oldukça önemli bir hazinedir. Başlamış olan bu
yeni sanayi ötesi devrimine hazırlıklarımız tamamlanmış olup akademik dünya ile
iç içe, diğer gelişmiş ülkeler ile rekabet edebilecek düzeyde çalışmalarımız
hızla devem etmektedir. 

Keywords

Sağlık, büyük veri

The value of big data in health

Abstract

It is not surprized to see how the storage of
data increases in the era of knowledge. On the other hand, without examining
this huge data truely and wisely, huge amount of financial and human source
could be waisted indeed. Besides huge storages, in order to examine this data,
evidence based methods are needed as well. In the recent years, great steps for
the storage of data were taken in Turkey. These health information storages,
built in Health Ministry and Social Security Department, are valuable not only
to lead health policy, but also for health research. All the preparations are
ready for the new post-industrial era, which also known as era of knowledge,
and together with academic world of our country, the studies are going on fast
as they are in developed countries.          

 

Keywords

Health, big data

References

• 1. Büyük Veri ve Açık Veri Analitiği: Yöntemler ve Uygulamalar. Editörler Şeref Sağıroğlu ve Orhan Koç. Grafiker Yayınları, 2017, Ankara, Türkiye.
• 2. Tozun, N. Ozdogan O(2), Cakaloglu Y(3), Idilman R(4), Karasu Z(5), Akarca U(5), Kaymakoglu S(6), Ergonul O(7). Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect, 2015. 21(11): p. 1020-6.
• 3. Arici M(1), Turgan C, Altun B, Sindel S, Erbay B, Derici U, Karatan O, Erdem Y, Hasanoglu E, Caglar S; Turkish Society of Hypertension and Renal Diseases. Hypertension incidence in Turkey (HinT): a population-based study. Hypertens. 2010 Feb;28(2):240-4. doi: 10.1097/HJH.0b013e328332c36b.
• 4. Hadem J(1), Tacke F, Bruns T, Langgartner J, Strnad P, Denk GU, Fikatas P, Manns MP, Hofmann WP, Gerken G, Grünhage F, Umgelter A, Trautwein C, Canbay A; Acute Liver Failure Study Group Germany. Etiologies and outcomes of acute liver failure in Germany. Clin Gastroenterol Hepatol. 2012 Jun;10(6):664-9.e2.
• 5. Simsek H(1), Pinar A, Altinbas A, Alp A, Balaban YH, Buyukasik Y, Ozcebe O, Hascelik G, Gedikoglu G, Tatar G. Cutoff level to detect heterozygous alpha 1 antitrypsin deficiency in Turkish population. J Clin Lab Anal. 2011;25(4):296-9. Gurol E(1), Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol. 2006;21(4):299-305.
• 6. Altinbas A, Baser E, Burkan A, Ertugay E, Kariburyo MF, Baser O. Retrospective analysis of total direct medical costs associated with hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey. J Viral Hepat. 2014 Nov;21(11):794-801.
• 7. Baser O, Altinbas A, Baser E, Kariburyo MF. Economic Impact and Complications of Treated and Untreated Hepatitis C Virus Patients in Turkey. Value in Health Regional Issues. 2015; 7c: 42 – 4 8.
• 8. Altinbas A(1). A quick overview to the early phase clinical trials of Simtuzumab®: Are we loosing the most promising anti-fibrotic product? Med Hypotheses. 2017 Oct;108:159-160.
• 9. Verstockt B(1), Ferrante M(1), Vermeire S(1), Van Assche G(2). New treatment options for inflammatory bowel diseases. J Gastroenterol. 2018 Mar 19.
• 10. İçli F(1), Altundağ K, Akbulut H, Paydaş S, Başaran G, Saip P, Doğu GG, Eralp Y, Uslu R, Sevinç A, Onur H, Mandel NM, Sezgin C, Altınbaş M, Güler N, Işıkdoğan A, Gökmen E, Uygun K, Üstüner Z, Yaren A, Demirkan B, Coşkun U, Ata A, Özkan M, Arican A. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast Cancer. 2015 Sep;22(5):480-5.
• 11. Onal IK(1), Beyazit Y, Altinbas A, Kurt M, Arhan M. Maintenance therapy for Crohn's disease: should it be indefinite? Eur J Gastroenterol Hepatol. 2015 Oct;27(10):1115-25.
• 12. Baser O(1). Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006 Nov-Dec;9(6):377-85.
• 13. Baser O, Baser E, Altinbas A, Burkan A. Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey. Health Econ Rev. 2013 Mar 12;3(1):5.
• 14. Baser O(1), Baser E, Altinbas A, Burkan A. Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey. Health Econ Rev. 2013 Mar 12;3(1):5.
• 15. Corey KE(1)(2), Kartoun U(2)(3), Zheng H(2)(4), Chung RT(1)(2), Shaw SY(2)(3). Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016 May;111(5):671-6.
• 16. Baser O(1), Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. High cost patients for cardiac surgery and hospital quality in Turkey. Health Policy. 2013 Feb;109(2):143-9.